Hot Features
プレミアム
ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
Horizon Technology Finance Announces First Quarter 2023 Financial Results PR Newswire FARMINGTON, Conn., May 2, 2023 - First Quarter 2023 Net Investment Income per Share of $0.46; NAV per Share...
Sélectionnée par le gouvernement canadien pour recevoir un financement supplémentaire, portant le soutien à un total de 10 millions de dollars à ce jour pour le développement clinique et la...
IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious...
Rapidly progressing DPX-COVID-19, including Health Canada agreement on Phase 1 clinical study design protocol, with preliminary results expected in fall 2020 Confirmed $4.75M of non-dilutive...
Ces subventions d’un total de 4,75 millions soutiendront la fabrication du vaccin et l’étude clinique de phase 1 IMV Inc. (Nasdaq: IMV; TSX: IMV), une société biopharmaceutique (la « Société »...
Contribution totalling Cdn$4.75 Million will support Phase 1 clinical development and manufacturing of DPX-COVID-19 IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company...
IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines to fight against...
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that company management will present at BTIG’s Virtual...
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced the...
Reçoit l’accord de Santé Canada à l’égard du design d’un essai clinique de phase 1, lequel comprendra aussi une cohorte d'adultes âgés de 56 ans et plus Formulation cGMP et développement du...
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 1.12 | 1.12 | 1.12 | 0 | 0 | CS |
| 4 | 0 | 0 | 1.12 | 1.12 | 1.12 | 0 | 0 | CS |
| 12 | 0 | 0 | 1.12 | 1.12 | 1.12 | 0 | 0 | CS |
| 26 | 0 | 0 | 1.12 | 1.12 | 1.12 | 0 | 0 | CS |
| 52 | 0 | 0 | 1.12 | 1.12 | 1.12 | 0 | 0 | CS |
| 156 | -14.38 | -92.7741935484 | 15.5 | 19.3 | 0.62 | 19324 | 7.3549774 | CS |
| 260 | -51.48 | -97.8707224335 | 52.6 | 92.5 | 0.62 | 78956 | 38.16654523 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
